Short Interest in AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Declines By 40.8%

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) saw a significant decrease in short interest in July. As of July 31st, there was short interest totaling 913,892 shares, a decrease of 40.8% from the July 15th total of 1,543,826 shares. Based on an average daily trading volume, of 741,607 shares, the short-interest ratio is currently 1.2 days. Approximately 6.3% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Separately, Ascendiant Capital Markets lowered their price objective on shares of AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating for the company in a report on Monday, June 1st. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, AIM ImmunoTech presently has an average rating of “Buy” and a consensus target price of $9.00.

Institutional Investors Weigh In On AIM ImmunoTech

A hedge fund recently bought a new position in AIM ImmunoTech stock. Corient Private Wealth LLC bought a new stake in shares of AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 10,001 shares of the company’s stock, valued at approximately $87,000. Corient Private Wealth LLC owned approximately 1.31% of AIM ImmunoTech as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 12.02% of the company’s stock.

AIM ImmunoTech Stock Performance

Shares of AIM ImmunoTech stock opened at $0.22 on Monday. The firm has a market capitalization of $6.69 million, a P/E ratio of -0.07 and a beta of 1.20. The business has a fifty day simple moving average of $0.31 and a two-hundred day simple moving average of $0.56. AIM ImmunoTech has a 12 month low of $0.19 and a 12 month high of $2.98.

AIM ImmunoTech (NYSEAMERICAN:AIM) last announced its earnings results on Friday, August 7th. The company reported ($0.43) EPS for the quarter. The firm had revenue of $0.03 million for the quarter. Analysts predict that AIM ImmunoTech will post -0.63 earnings per share for the current year.

About AIM ImmunoTech

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.